Literature DB >> 20631633

Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness.

Yoko Yamaguchi1, Genichiro Ishii, Motohiro Kojima, Kiyotaka Yoh, Hajime Otsuka, Yoichi Otaki, Keiju Aokage, Shingo Yanagi, Kanji Nagai, Yutaka Nishiwaki, Atsushi Ochiai.   

Abstract

INTRODUCTION: The term tumor budding has been applied to single cells or small clusters of up to four cells within the stromal tissue at the invasive margin of colorectal cancers. This morphologic feature is increasingly being recognized as an adverse prognostic factor. The purpose of this study was to evaluate the clinicopathologic significance of tumor budding in adenocarcinomas of the lung.
METHODS: We investigated the relationship between tumor budding and clinicopathologic parameters of adenocarcinomas of the lung and the prognostic significance of tumor budding by reviewing the cases of 201 consecutive patients who had undergone complete resection of adenocarcinoma of the lung measuring 30 mm or less in diameter. We examined immunohistochemical profile of budding cells (BCs) by immunohistochemical staining with 14 antibodies.
RESULTS: Tumor budding was observed in 78 (43.1%) of the 181 cases with invasive adenocarcinoma. The presence of tumor budding was significantly associated with lymph node metastasis (p = 0.005), pathologic stage (p < 0.001), vascular invasion (p = 0.003), lymphatic invasion (p = 0.009), and pleural invasion (p = 0.029). Examination of the relation between the presence of tumor budding and the predominant histologic subtype revealed that the predominant papillary subtype was significantly associated with the presence of tumor budding (p = 0.0023), whereas the predominant bronchioloalveolar carcinoma subtype was significantly associated with the absence of tumor budding (p < 0.001). The overall 5-year survival rates of the group with budding and the group without budding was 67.5% and 88.3%, respectively, and difference was significant (p = 0.0057). Compared with cancer cells forming nests, BCs displayed reduced expression of cellular adhesion molecule, E-cadherin, and beta-catenin (p < 0.05 and p < 0.05, respectively) and increased expression of laminin5-gamma2 (p < 0.05). However, BCs displayed reduced expression of differentiation marker, surfactant protein A (p < 0.05). Multivariate analysis revealed that tumor budding was significant independent prognostic factor of the small-sized adenocarcinoma of the lung.
CONCLUSIONS: Our data showed that tumor budding in adenocarcinoma of the lung is a distinct morphologic feature that has biologic and prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631633     DOI: 10.1097/JTO.0b013e3181eaf2f3

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  30 in total

1.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

2.  Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma.

Authors:  Cheng Wang; Hongzhang Huang; Zhiquan Huang; Anxun Wang; Xiaohua Chen; Lei Huang; Xiaofeng Zhou; Xiqiang Liu
Journal:  J Oral Pathol Med       Date:  2011-04-12       Impact factor: 4.253

3.  Prognostic and predictive factors in gingivo buccal complex squamous cell carcinoma: role of tumor budding and pattern of invasion.

Authors:  B V Manjula; Suni Augustine; Sumithra Selvam; A Mathan Mohan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-10-31

4.  Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope?

Authors:  Fabio Grizzi; Giuseppe Celesti; Gianluca Basso; Luigi Laghi
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 5.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

6.  Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.

Authors:  Yukiko Matsuo; Kazu Shiomi; Dai Sonoda; Masashi Mikubo; Masahito Naito; Yoshio Matsui; Tsutomu Yoshida; Yukitoshi Satoh
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-01       Impact factor: 4.553

7.  Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma.

Authors:  Nao Aramaki; Genichiro Ishii; Eiji Yamada; Masahiro Morise; Keiju Aokage; Motohiro Kojima; Tomoyuki Hishida; Junji Yoshida; Norihiko Ikeda; Masahiro Tsuboi; Atsushi Ochiai
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-18       Impact factor: 4.553

8.  Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Kaitlin M Woo; Camelia S Sima; David J Finley; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

9.  Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer.

Authors:  Hongxia Hao; Zhiguo Zhou; Shulong Li; Genevieve Maquilan; Michael R Folkert; Puneeth Iyengar; Kenneth D Westover; Kevin Albuquerque; Fang Liu; Hak Choy; Robert Timmerman; Lin Yang; Jing Wang
Journal:  Phys Med Biol       Date:  2018-05-02       Impact factor: 3.609

10.  Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients.

Authors:  Ryota Masuda; Hiroshi Kijima; Naoko Imamura; Naohiro Aruga; Yusuke Nakamura; Daisuke Masuda; Haruka Takeichi; Nobusuke Kato; Tomoki Nakagawa; Makiko Tanaka; Sadaki Inokuchi; Masayuki Iwazaki
Journal:  Mol Med Rep       Date:  2012-08-27       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.